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Available online 11 October 2016The hallmarks of cancer capture the most essential phenotypic characteristics of malignant transformation and
progression. Although numerous factors involved in this multi-step process are still unknown to date, an ever-
increasing number of mutated/altered candidate genes are being identiﬁed within large-scale cancer genomic
projects. Therefore, investigators need to be aware of available and appropriate techniques capable of determin-
ing characteristic features of each hallmark.
We review the methods tailored to experimental cancer researchers to evaluate cell proliferation, programmed
cell death, replicative immortality, induction of angiogenesis, invasion and metastasis, genome instability, and
reprogramming of energy metabolism. Selecting the ideal method is based on the investigator's goals, available
equipment and also on ﬁnancial constraints. Multiplexing strategies enable a more in-depth data collection
from a single experiment — obtaining several results from a single procedure reduces variability and saves
time and relative cost, leading to more robust conclusions compared to a single end point measurement. Each
hallmark possesses characteristics that can be analyzed by immunoblot, RT-PCR, immunocytochemistry, immu-
noprecipitation, RNAmicroarray or RNA-seq. In general,ﬂow cytometry, ﬂuorescencemicroscopy, andmultiwell
readers are extremely versatile tools and, with proper sample preparation, allow the detection of a vast number
of hallmark features. Finally, we also provide a list of hallmark-speciﬁc genes to be measured in transcriptome-
level studies.
Although our list is not exhaustive,we provide a snapshot of themostwidely usedmethods,with an emphasis on
methods enabling the simultaneous evaluation of multiple hallmark features.iomarker Re
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Tumorigenesis is a multi-step process that progressively converts
normal cells intomalignancies. The six hallmarks characterizing neopla-
sia (sustaining proliferative signaling, evading growth suppressors,
resisting cell death, enabling replicative immortality, inducing angiogene-
sis, and activating invasion and metastasis) were delineated in Hanahan
and Weinberg's seminal work compressing decades of cancer research
data into a single paper [1]. Since then further features of malignant
conversion have been described. Genomic instability generates random
mutations, while inﬂammation nurtures and accelerates tumorigenesis.
Reprogramming of energy metabolism and avoiding immune destruction
emerged as important supporting features and epigenetics was
accepted as a player of equal importance to genetic abnormalities in
the initiation and progression of cancer. Finally, development of cancer
can only be understood by integrating the dynamic signaling circuitry
between cells and the tumor microenvironment [2].
Hallmark capabilities are regulated by partially redundant sig-
naling pathways; the signiﬁcance of these pathways depends on
the tumor's underlying molecular features. Choosing an appropriate
in vitro assay to monitor a given hallmark among the available op-
tions is a challenging task, especially for concurrent analysis of mul-
tiple hallmarks. Combining assays provides more information, but
at the same time multiplexing requires compatibility for parallel
or sequential measurements. The cost and speed of an assay, a
need for a quantitative real-time or endpoint measurement, and
the equipment required should be considered carefully to selectan optimal solution. Understanding the pros and cons of each
assay is crucial.
In this review we attempt to summarize the most frequently used
in vitro assays for analyzing each hallmark in cell culture.We particular-
ly emphasize assay combinations to study multiple hallmarks simulta-
neously. Animal models, e.g. mouse or zebraﬁsh, are popular to
reproduce hallmark features; however, the cost and the required special
procedures put animal models beyond the scope of this review. Also,
hallmarks involving the immune system were excluded because of the
difﬁculty of assessing them in cell culture-based experiments.
2. Hallmarks of cancer
2.1. Sustaining proliferative signaling and evading growth suppressors
Unlimited proliferation is the predominant feature of all cancer cells.
Sustaining proliferative signaling and evading growth suppressors is de-
ﬁned by the number of healthy cells in a sample and/or by the mainte-
nance of proliferative ability over time. Assays are based on biochemical
events speciﬁc to living cells, such asmetabolic activity and cellular ATP,
membrane integrity, DNA synthesis, protein content, and the imped-
ance of living cells. An alternativeway tomeasure cells' ability to under-
go sufﬁcient proliferation is to assess colony formation by single cells.
2.1.1. Metabolic activity
Reduction of substrates to a ﬁnal product by intracellular enzyme ac-
tivity in living cells can be assessed by a colorimetric assay. The degree
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but rather to the activity of an integrated set of enzymes of the cellular
environment, which utilize the cofactor, NADH, and various other sub-
strates [3]. Thismethod permits only amoderately robustmeasure of vi-
ability; however, the ease of use and potential for high throughput
analysis in multiwell plates has widely popularized it. The most fre-
quently used tetrazolium compound (MTT) is reduced to formazan
[4]. More recently-developed tetrazolium analogs (XTT, MTS, WST-1,
WST-8) are used in conjunction with intermediate electron acceptors
[3] and are converted to water-soluble formazan [5–8]. Eliminating
the solubilization step simpliﬁes the protocol and allows real-timemea-
surement ofmetabolic activity. The deep blue Alamar Blue (resazurin) is
reduced to the pink, ﬂuorescent resoruﬁn [9]. Acetoxymethyl ester of
calcein (Calcein AM) cleaved by esterases within live cells produces
green ﬂuorescence, while dead cells exhibit red ﬂuorescence. Quantiﬁ-
cation with a ﬂuorescence microplate reader permits determination of
the ratio of viable/dead cells in a population. Bioluminescence assays
(e.g. CellTiter-Glo) measuring cellular ATP by the development of mu-
tant luciferase perform with better reproducibility and sensitivity com-
pared to MTT assays and are particularly useful when assessing cell
viability in low density cell populations [10–13]. Table 1 summarizes
the most frequently used enzymatic assays and their limitations.
2.1.2. Protein content
The presence of living cells is assayed by SRB (sulforhodamine B), a
red ﬂuorescent aminoxanthene dye. This compound produces a change
detectable via colorimetry as its sulfonic group binds to basic amino acid
residues in proteins, to give an estimation of total proteinmass, which is
directly proportional to cell number [14]. In contrast to MTT, SRB stain-
ing is not dependent onmitochondrial function; therefore less variation
is observed between cell lines [15]. SRB has better linearity and higherTable 1
Summary of intracellular metabolic assays available to measure cellular proliferation.
Assay Substance used Pro
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com
usesensitivity than other colorimetric assays, and is comparable to those
achieved with standard ﬂuorescent dye staining methods [16,17]. The
method is very cheap as it requires only a multiwell reader, has a stable
endpoint, and the reagent can be stored indeﬁnitely.
2.1.3. Membrane integrity — dye exclusion assays
Several methods employ dyes which diffuse passively through
damaged membranes, while they are excluded by healthy cells. First,
the trypan blue exclusion assay [18] is cheap, simple and still widely
used. Viable cells are counted with a hemocytometer or an automated
electronic particle counter, and the percentage of viable cells is
calculated [19]. Second, healthy and early apoptotic cell membranes
are impermeable to the red-ﬂuorescent propidium iodide (PI), which
intercalates between base pairs of double-stranded DNA. Uptake is
assessed by ﬂow cytometry allowing single cell level analysis [20,21].
Finally, SYTOX Green Stain and YO-PRO-1 can provide more reliable
results than PI-based tests in ﬂow cytometric assays [22]. The major
drawback of the dye exclusion assays is the cytotoxic nature of most
probes, preventing long term use, and inaccurate automated readings
if the cells tend to cluster.
Cells with a compromisedmembrane release substances such as lac-
tate dehydrogenase (LDH) [23]. Fluorescence-based detection methods
have been developed to perform LDH measurement directly in culture
wells with a spectrophotometer containing a mixture of viable and
dead cells without damaging the membranes of the viable cell popula-
tion. Limitations are the low selectivity and the relatively short half-
life of LDH [24].
2.1.4. DNA synthesis
Incorporation of radiolabeled DNA precursor 3H-thymidine into new
strands of chromosomal DNA or more recent analogs, BrdUs Cons
ry robust, suitable for most cell lines,
ay stays linear from 200 to 1000 up to
,000–100,000 cells/well. Good
relation with radioactive cell counting.
Endpoint assay. Incomplete solubilization,
the presence of phenol red, overconﬂuent
cells and the lack of glucose interferes with
enzyme activity [4,263]. Reducing
compounds converting MTT (such as
ascorbic acid, sulfhydryl-containing
compounds) can alter the results
[264,265].
itable for real time measurement. More
sitive and less cytotoxic than MTT.
Not suitable for cells with lower metabolic
activity due to relatively elevated
background levels. The presence of DTT,
mercaptoethanol, L-cysteine, L-ascorbic
acid, cyanide, azide, and changes in
environmental oxygen distorts the results
[5].
re sensitive than MTT and more stable
n XTT.
Optimization advisable for each cell type
[6,266,267]
re stable than XTT and MTS. Optimization is required for each cell type
[267].
n-destructive method. Higher
sitivity compared to the other
razolium salts. Correlates well with the
–thymidine incorporation assay.
Optimization is required for each cell type
[8].
ry sensitive, 80 cells provide a
roducible signal, linear reading in the
ge of 50–50,000 cells. More sensitive
n tetrazolium-based methods. Fast,
ple and relatively cheap. Stable signal.
ows multiplexing.
At higher cell density or at metabolically
very active cells hydroresoruﬁn is
produced distorting the results. Necessary
to test crossreactivity with any compound
to be tested, without any cells in the
medium [268,269].
naffected by pH change, and has a
erior cellular retention [270].
Cytotoxic for several cell lines [271].
her reliability and sensitivity compared
MTT, can detect as few as 10 cells/well.
orter protocol and less handling
pared to other methods. Especially
ful in low density populations.
Endpoint assay, cell lysis required. ATP
varies signiﬁcantly in cells [272,273].
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assess de novo DNA synthesis [25–27]. During the S phase of the cell
cycle they are integrated into the nuclear DNA [28]. 3H-thymidine de-
tection requires a scintillation beta-counter, whereas BrdU can be
detected by antibodies, allowing analysis by ﬂow cytometry or by im-
munohistochemistry, eliminating the need for radioactive labeling.
BrdU is toxic and mutagenic, alters cell cycle and the fate of the cells
that incorporate it, thus appropriate controls are required [29,30]. In
contrast to BrdU, the newest analog EdU does not require DNA denatur-
ation by exposing cells to HCl, heat or DNAse, and its detection is rapid
and highly sensitive [27]. BrdU and EdU are thought to provide themost
reliable and direct index of proliferation.
2.1.5. Impedance of a living cell
The traditionalmethods, usually based on end-point analysis, provide
limited information about cell physiology. The non-invasive, label-free
real-time cell analyzer platforms (RTCA) are capable of continuously
monitoring biological processes, such as proliferation, migration and
invasion, based on the impedance of living cells grown on surfaces,
thereby permitting conductivity measurements [31]. Platforms such as
xCELLigence RTCA are commercially available; gold microelectrode ar-
rays line the bottoms of the wells and create an electric ﬁeld with the in-
troduced cells acting as insulators, such that net cell adhesion can be
measured. Cell Index (CI) is an arbitrary unit reﬂecting the electronic
cell-sensor impedance that directly correlates with the number of viable
cells. The RTCA is also suitable for co-culture studies. When testing cyto-
toxic compounds, the effects of toxic insult are often transient. RTCAs are
ideal to determine the optimal time points for end-point measurements
and the temporal proﬁle of drug responsiveness [32].
2.1.6. Live-cell time-lapse imaging
Commercially available, the IncuCyte™ system allows real-time, au-
tomated monitoring of cell proliferation based on live cell time-lapse
imaging. The system monitors proliferation by analyzing conﬂuence
and allows the separation of living and apoptotic cells by labeling
reagents. Moreover, transfecting the nucleus with green or red ﬂuores-
cent protein (GFP/RFP) tagged constructs allows the quantiﬁcation of
cell number and the monitoring of migration/invasion. A major advan-
tage is the nearly unlimited real-time analysis, but one must consider
the high initial cost of the setup. Performance of real-time systems
(xCELLigence, IncuCyte™) was outstanding in sub-conﬂuent cell
cultures, but these were outperformed by endpoint assays at full
conﬂuence [33].
2.1.7. Colony formation assay
The clonogenic assay tests the effects of external stress signals on cell
survival, namely the cell's ability to undergo sufﬁcient proliferation to
form a colony. This assay is especially useful to assess long-term effects,
such as survival after irradiation. It is suitable for use with any type of
cell that can be grown in culture. Sufﬁcient colonies generally contain
at least 50 cells. Colony counting is usually done manually with a pen
or with automated gel count systems, such as the Oxford Optronix.
These systems provide additional information, such as colony size, are
able to handle high plate throughput and offer consistent counting.
However, themethod is also time consumingwith extended incubation
times, plus colony formation ability of cells differs [34]. Cell architecture
and conformation inﬂuence cellular responsiveness [35,36].
Two-dimensional assays limit intercellular communication; there-
fore 3D culture and assay methods are under development [37]. The
soft agar assay determines anchorage-independent proliferation, a
characteristic of cancer cells, as normal cells undergo anoikis when
they detach from the extracellular matrix. Cells are grown in soft agar,
with a denser agar beneath to prevent adhesion to the culture plate,
where transformed, but not normal, cells form colonies. The assay al-
lows the study of tumor suppressive function of signaling molecules
and is often predictive of tumorigenicity in vivo [38]. The traditionalassay requires weeks for completion and does not allow cell retrieval;
however incorporation of ﬂuorimetric dyes allows quantitative, high-
throughput colony counting and the use of specialized agars permits
viable cell retrieval (e.g. CytoSelect™multiwell transformation assays).
Assays detecting living cells and proliferation in cell cultures are
summarized in Table 2. Sustained proliferation and evasion of growth
suppression can also be estimated by analyzing gene expression of key
enzymes involved (Table 6) [39,40].
2.2. Resisting cell death
Apoptosis is an active form of cell death, an organized process that
leads to programmed self-destruction. Activation of apoptotic pathways
alters morphology and cell surface, leads to genome fragmentation and
mitochondrial dysfunction and fragments the dying cells in the ﬁnal
phases into apoptotic bodies [41]. It is a relatively swift process, from
initiation to completion lasting less than 3 h. The complex signaling
pathways are strongly regulated, enabling opportunities to detect and
evaluate the process, although the timing of analysismust be optimized
as some proteins only appear transiently. Twomain apoptotic pathways
are recognized. The extrinsic pathway is mediated by cell surface death
receptors such as Fas or TNF-R, while the intrinsic pathway is activated
by internal damage leading to mitochondrial cytochrome c release. The
two pathways are linked, mutually inﬂuence each other and ultimately
converge on a single execution pathway modulated by caspase
activation [42].
2.2.1. Morphological changes
Morphological changes such as cell size reduction, nuclear
condensation and fragmentation, the presence of large clear vacuoles,
andmembrane blebbing can be quantiﬁed by lightmicroscopy or trans-
mission electron microscopy. Live cell time-lapse imaging allows real-
time, automated monitoring of cell proliferation and morphology by
high-deﬁnition phase-contrast images [43]. Additionally, each of these
cellular modiﬁcations can be rapidly measured by ﬂow cytometry [44].
2.2.2. Genome fragmentation
During apoptosis the chromatin is fragmented by endonucleases, the
nucleus destructs (karyorrhexis), and cells lose oligo-nucleosomal
fragments. DNA laddering is a common end result that can be detected
as genome fragments by gel electrophoresis [45]. The loss of genome
fragments leads to reduced staining of apoptotic cells with DNA-
intercalating ﬂuorochromes such as propidium iodide, which is
measured easily and accurately by ﬂow cytometry [20].
The TUNEL (terminal deoxynucleotidyl transferase (TdT)-mediated
dUTP Nick End Labeling) assay is a common method to detect early
apoptosis. It is based on the appearance of 3′-OHDNA termini generated
by endonucleases [46]. Terminal transferase (TdT) is used to add
ﬂuorescently-labeled dUTP to the free DNA double- and single-
stranded breaks [47,48]. Such DNA breaks can also be detected in cell
suspensions by ﬂow cytometry orﬂuorescencemicroscopy by apoptosis
enzyme-linked immunoassay based on immunostaining [49].
2.2.3. Plasma membrane alterations
Phospholipids are asymmetrically distributed on the inner and outer
surfaces of the plasma membrane. Apoptotic cells are unable to main-
tain the phospholipid asymmetry, thus phosphatidyl-serine (PS) ap-
pears on the outer surface. PS can be detected using PS-binding
anticoagulant Annexin V-FITC. FITC or other ﬂuorescent-labeled apo-
ptotic cells then are visualizedwith ﬂuorescencemicroscopy or counted
by ﬂow cytometry [50,51]. UsingAnnexin V-FITC in combinationwith PI
permits viable (double negative), early apoptotic (Annexin V-FITC
positive/PI negative) and late apoptotic (PI positive) cells to be distin-
guished [51].
Table 2
Methods investigating cell viability and proliferation.
Feature Substance Detection method Principle
Metabolic activity MTT
XTT
MTS
WST-1
WST-8
Alamar Blue (resazurin)
Calcein AM
Intracellular ATP
Colorimetric
Colorimetric
Colorimetric
Colorimetric
Colorimetric
Fluoro/colorimetric
Fluorometric
Bioluminescense
Redox reaction; colorless compounds are reduced by
living cells to brightly colored metabolites
Redox reaction, nonﬂuorescent resazurin is converted
by reduction to a ﬂuorophore pink resoruﬁn
Intracellular esterases convert Calcein AM to ﬂuorescent calcein
Changes in ATP are correlated with viable cells
DNA synthesis BrdU, EdU
3H-thymidine
Flow cytometry, IHC
Scintillation beta-counter
Substances are incorporated into new strands during
de novo DNA synthesis
Membrane integrity Trypan blue
Propidium iodide
SYTOX
Yo-PRO-1
Lactate dehydrogenase
Hemocytometer, Fluorometric
Fluorometric
Fluorometric
Fluorometric
Fluorometric
Dead cells or substances released from a cell take up the dye
Protein content sulforhodamine B Colorimetric Binds amino acid residues in proteins through its sulfonic group
and gives an estimation of total protein mass
Impedance of living cells – Real time cell analyzer system (xCelligence) Microelectrode array at the bottom of the well detects impedance
of living cells
Live-cell time-lapse imaging – IncuCyte™ Real-time, automated monitoring of cell proliferation
based on live-cell time-lapse imaging
Colony formation – Colony counting (manually or gel count systems) Cells grown in culture
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Assays to monitor mitochondrial membrane alterations allow the
recognition of changes in the early phase of the intrinsic pathway
activation. The collapse of the electrochemical gradient across themito-
chondrial outer membrane decreases mitochondrial transmembrane
potential (ΔΨm), leading to increased membrane permeability, detect-
able by several sensitive cationic dyes (listed in Table 3) [52,53]. Nor-
mally accumulating in the mitochondria, during apoptosis these
cationic dyes diffuse into the cytoplasm where they can be detected
by altered ﬂuorescent emission [54].2.2.5. Intracellular calcium concentration
Altered intracellular Ca2+ concentration is one of the ﬁrst signs that
a cell is committed to apoptosis initiated by the Bcl-2 family (intrinsic
pathway; see below). Release of the key apoptotic enzyme, cytochrome
c, depends on the emission and uptake of Ca2+ from endoplasmic
reticulum andmitochondria, respectively. The Ca2+ levels of the cytosol
or mitochondria can be measured by selective ﬂuorescent dyes
(Table 3) [55,56].2.2.6. Detection of apoptosis regulators
Cytochrome c can be detected in cell extracts by immunoprecipitation
or immunoblotting with cytochrome c-speciﬁc monoclonal antibodies
(mAbs). Subcellular detection of exogenous GFP-tagged cytochrome c is
possible by ﬂuorescence microscopy [57,58]. Cytochrome c is also
released extracellularly from cells that are committed to apoptosis. In
cell cultures it can be detected in the media in the early phase and is
speciﬁc to apoptosis, but not to necrosis [59].
Another group of proteins regulating apoptosis is the Bcl-2 family that
facilitates (Bcl-2 subfamily) or inhibits (Bax and BH-3-only subfamily)
cell survival (Table 3) [60]. Cell surface receptors Fas (Apo-1, CD95) and
their ligand (FasL) serve as mediators. Commercially available mAbs
raised against human apoptotic proteins (Bcl-2, Bax, Fas, FasL) can be
used in ﬂow cytometry, immunoblot, and immunochemistry [61,62].
Members of the CDK (cyclin-dependent kinase) family play a key role
in the regulation of both mitosis and apoptosis. Activation of CDK2 is re-
quired for apoptosis and is controlled by p53 and Bcl2-family proteins
[63]. The detection of CDK2 along with associated proteins is based on
immunoprecipitation followed by immunoblots [64].2.2.7. Detection of caspases
Caspases, belonging to the cysteine protease family, are irreversibly
activated during apoptosis and other cellular processes, such as inﬂam-
mation or differentiation. An intrinsic or extrinsic death signal activates
the proteolytic cascade of caspases promoting their aggregation into di-
mers or macromolecular complexes, resulting in controlled demolition
of cellular components.With speciﬁc antibodies, caspases can be identi-
ﬁed by immunoprecipitation or immunoblot, may be labeled with
ﬂuorescent probes, and detected by ﬂuorescence microscopy [65],
ﬂow cytometry [66], or laser scanning cytometry [67]. The IncuCyte™
technology allows the direct addition of the caspase 3/7 apoptosis
assay reagent to tissue culture wells, preventing cell loss. The inert,
non-ﬂuorescent reagent freely crosses the cell membrane, and after
cleavage by caspase 3, releases a green DNA-binding dye. The
ﬂuorescent staining of the cleaved substrate can be monitored by live
cell imaging [43].
Small labeled peptide-based substrates conjugated to ﬂuorogenic or
chromogenic groups are released and detected spectrophotometrically
when the substrate is cleaved by a particular caspase [68–70]. Synthetic
caspase inhibitors (Fluorochrome Inhibitor of Caspases; FLICA) bind to
functional groups of active sites of caspases [71].
Detecting cleavage of themultiple caspase substrates inside a cell is a
common method to assess caspase activity. One of the most frequently
used targets, a DNA repair enzyme, Poly(ADP)ribose polymerase
(PARP), is identiﬁed by speciﬁc antibodies (together with mAb for en-
tire, uncleaved PARP) and detected by immunoblot [72], ﬂuorescence
microscopy [73] or ﬂow cytometry [74].
A detailed comparison of apoptosis detection assays is included in
Table 3. Hallmark features for resisting cell death and their applicable
detectionmethods are presented in Fig. 1A. The occurrence of apoptosis
can also be identiﬁed by analyzing the gene expression of key enzymes
and regulators (Table 6) [75,76].2.3. Enabling replicative immortality
Normal cells pass through a limited number of cell cycles, followed
by an irreversible, nonproliferative state (senescence), and ﬁnally
death. Telomeres protect the termini of chromosomes and are central
in preventing uncontrolled proliferation [77]. The size of the telomeric
DNA determines the cell's maximum capacity for division before
Table 3
Comparison of apoptosis detection assays.
Apoptosis features Detection target Method Detection methods Principle
Morphology alterations Changes in cell
morphology
Light microscopy
Electron microscopy
Time-lapse microscopy
Flow cytometry
Cell staining [44]
Genome
fragmentation
Genome fragments DNA laddering Gel electrophoresis DNA staining [45]
Loss of genome fragments DNA content analysis Flow cytometry DNA staining: PI (propidium iodide), acridine orange,
ethidiume bromide, Hoechst 33,342, etc. [20]
Free 3′-OH DNA ends TUNEL Fluorescence microscopy
Flow cytometry
Labeling DNA breaks by terminal transferase with
ﬂuorescently marked dUTP [46-48]
ssDNA Apoptosis
enzyme-linked
immunoassay
Fluorescence microscopy
Flow cytometry
Immunostaining single-stranded DNA with
monoclonal antibodies (mAbs) [49]
Plasma membrane
alteration
Phospholipids in the
outer side of PM
Annexin binding assay Fluorescence microscopy
Flow cytometry
PS-binding Annexin V labeled with ﬂuorescein
isothiocyanate (FITC) or phycoerythrin [50, 51]
Intracellular enzymes
in media
LDH activity assay Spectrophotometric methods LDH enzyme reaction linked to NADH reduction
leads to absorbance changes of speciﬁc probes [274]
Mitochondrial
membrane
alteration
Increased mitochondrial
membrane permeability
Mitochondrial
membrane
potential assay
Spectrophotometric methods
Fluorescence microscopy
ﬂow cytometry
Cationic ﬂuorescent probes that responds
to the changes in Δψm such as: JC-1, DiOC6 ,
Rhodamine-123, CMXROS, TMRM, HE, NAO [52–54]
Intracellular calcium
concentration
Free Ca2+ levels Changes in intracellular
calcium
Spectrophotometric methods
Fluorescence microscopy
Flow cytometry
Speciﬁc dyes consist of Ca2+ chelating molecules that
undergo
changes in their ﬂuorescence excitation and emission
properties (Fura-2; Indo-1; Rhod-2; Fluoro-3/Fluoro-4)
[55,56]
Speciﬁc regulators Cytochrome c Intracellular
cytochrome
c detection
Immunoprecipitation
Immunoblot
Fluorescence microscopy
Using anti-cytochrome cmAbs [57,58]
Extracellular
cytochrome
c detection
Immunoprecipitation
Immunoblot
Fluorescence microscopy
Using anti-cytochrome cmAbs, alternative protocol [59]
Bcl-2 family, Fas and FasL,
CDK family
Direct detection Immunoprecipitation
Immunoblot
Flow cytometry
Using speciﬁc mAbs [61–64]
Caspase Direct detection Immunoprecipitation
Immunoblot
Flow cytometry
Fluorescence microscopy
IncuCyte™
Using speciﬁc mAbs for inactive (zymogen) or active
form of the proteins [65–67]
Live-cell imaging [43]
Caspase activity assay Caspase activity Spectrophotometric methods Small labeled peptide based substrates [68–70]
FLICA Spectrophotometric methods
Flow cytometry
Small labeled peptide based inhibitors [71]
PARP assay Immunoprecipitation
Immunoblot
Flow cytometry
Fluorescence microscopy
Using speciﬁc mAbs for cleaved or uncleaved
caspase target proteins such as PARP
(Poly(ADP)ribose polymerase) [72–74]
Abbreviations: PM: plasma membrane, PS: phosphatidyl-serine, LDH: lactate dehydrogenase, Δψm: mitochondrial membrane potential, DIOC6: n to 3,3′ dihexyloxacarbocyanine iodide,
CMXROS: chloromethyl-X-rosamine, TMRM: tetramethylrhodaminemethyl ester, HE: dihydroethidine, NAO: nonyl acridine orange, mAbs:monoclonal antibodies, FLICA: ﬂuorochrome-
labeled inhibitors of caspases assay PARP: poly(ADP)ribose polymerase.
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of telomeres, unprotected chromosomal termini undergo fusion
resulting in karyotypic disarray (aneuploidy) and cell death. Telome-
rase, a speciﬁc DNA polymerase, adds telomere hexanucleotide repeats
at the termini of telomeric DNA. It is nearly absent in normal cells, but its
expression is up-regulated to signiﬁcant levels in almost all types ofma-
lignant cells.2.3.1. Measuring the length of telomeres
Formany years, terminal restriction fragment analysis (TRF)was the
gold standard quantitative method to measure telomere length; it be-
came a reference for techniques developed thereafter. Restriction en-
zymes fully digest the genomic DNA but speciﬁcally avoid telomere
repeats, resulting in short genomic fragments, while simultaneously
leaving longer uncut telomeres. Fragments are resolved by agarose gel
electrophoresis and telomeres are identiﬁed through either Southern
blotting or in-gel hybridization using a labeled probe speciﬁc for
telomeric DNA [78–80]. TRF requires substantial amounts of genomic
DNA, prepared at least from 105 cells, and is relatively insensitive to
very short telomeres [81].Single Telomere Length Analysis (STELA) takes advantage of a
single-stranded 3′ G-rich overhang present at the end of all telomeres
[82]. Using the overhang as a speciﬁc template, an oligonucleotide linker
is annealed to the 5′ terminus of the telomere. After ampliﬁcation with
polymerase chain reaction (PCR) the products are Southern blotted and
probed with the speciﬁc subtelomeric sequence [83,84].
Quantitative ﬂuorescence in situ hybridization (qFISH) of telomere
repeats directly employs ﬂuorescent-labeled(CCTAA)n peptide nucleic
acid (PNA) probes on metaphase chromosomes. Once the PNAs speciﬁ-
cally hybridize to denatured telomere DNA repeats [85,86], the detected
signal is compared to standards of known telomere length with speciﬁc
Q-FISH image analysis software [87]. Themethod allows the quantiﬁca-
tion of telomere length in distinct cell populations within a single sam-
ple by antibody staining [88,89].
2.3.2. Telomerase activity
Telomerase activity is measured by TRAP (telomere repeat ampliﬁ-
cation protocol) or real-time quantitative PCR. TRAP is a PCR-based
assay based on the low substrate speciﬁcity of telomerase. During
elongation, telomerase from the cell extract adds telomeric repeats to
the telomere-imitating oligonucleotide, after which telomerase-
Fig. 1. Circos plot showing a panoramic viewof hallmark features (bold) and in vitromethods (italic) available for their examination for resisting cell death (A), replicative immortality (B),
genome instability (C), and reprogramming of energy metabolism (D). Please refer to the manuscript text for details regarding each component.
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tating and reverse) [90–92]. Different labels are incorporated into the
telomerase-synthesized DNA [93]. In the ﬁnal step the telomerase prod-
uct is visualized. The TRAP assay can be performed in both semi-
quantitative and quantitative modes [94]. Multiplexing can be achieved
by the microarray TRAP (MTRAP) [95]. In situ TRAP (FISH-TRAP) using
ﬂuorescent telomerase primers and in situ PCR can detect telomerase
activity in clinical specimens [96].
2.3.3. Senescence
Repeated cell division eventually leads to replicative senescence. Ex-
cessive extra- or intracellular stress, such as telomeric dysfunction, mi-
tochondrial retrogression, oxidative stress, DNA damage, or oncogene
activation also provoke stable cell-cycle arrest to prevent the spread of
damage to the next generation [97,98]. The ﬁrst identiﬁed marker was
the lysosomal senescence-associated β-galactosidase (SA-βgal) that
cleaves galactosidase from glycoproteins and is only functional at
pH 6.0 in senescent cells [99]. By cleaving the chromogenic substrate
X-gal at pH 6.0, senescent cells develop a blue stain detected by bright
ﬁeld or phase contrast microscopy. Using substrates that become
ﬂuorescent after cleavage, SA-βgal positive cells can be quantiﬁed by
ﬂuorescence microscopy, by ﬂuorescence-activated cell sorting (FACS)
for living cells, or by high throughput screening (HTS) on cell lysates
in multiwell plates [100]. Senescent cells are metabolically active and
secrete a complex mixture of factors referred to as the SASP (senes-
cence-associated secretory phenotype) [101]. The secretome, regulated
by transcription factors such as CEBPb and NF-kB, includes extracellular
proteases, matrix components, growth factors, pro-inﬂammatory cyto-
kines, and chemokines. The secretome can be evaluated by antibodyarrays [102]. In some cases, cellular senescence is a potent tumor sup-
pressive mechanism that stops the growth of cells at risk for malignant
transformation [103,104]. However, some cytokines and growth factors
are pro-tumoral and pro-invasive – rather than tumor suppressive –
and act by changing the tissue microenvironment and promoting mi-
gration and invasion [101].
The most frequently used methods and their impacts on detecting
hallmark features are illustrated in Fig. 1B. Cancer cell immortality can
be assessed by analyzing expression of key enzymes and regulators as
listed in Table 6 [101,102,105–107].
2.4. Inducing angiogenesis
Neoplastic cells induce angiogenesis to secure the tumor's require-
ments for nutrients and oxygen. A trait ﬁrst attributed solely to rapidly
growing macroscopic tumors, angiogenesis has later been identiﬁed in
microscopic pre-malignant lesions as well, in morphologically atypical
tissueswith an abnormally high occurrence of cancer. A prototypical an-
giogenesis inducer is vascular endothelial growth factor-A (VEGF-A),
that coordinates vessel growth, homeostatic survival of endothelial
cells and wound healing. Up-regulation of VEGF and ﬁbroblast growth
factor (FGF) expression in tumors as compared to normal tissue is
attributed to oncogenes like KRAS and hypoxia [2,108,109].
Two approaches have been widely used to simulate the complex
process of angiogenesis [110,111]. First, the response to exogenous
stimulatory or inhibitory agents, proliferation, differentiation, and mi-
gration of endothelial cells can be studied in cultured HUVEC (human
umbilical vein endothelial cells) and HuDMEC (human dermal
microvascular endothelial cells) cell lines. The proliferative ability of
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genesis viameasuring endothelial proliferation [112].
Endothelial cells respond to angiogenic factors with increased
motility, and move along the gradient of angiogenesis-inducing factors
(e.g. VEGF), a process called chemotaxis. Migration is assessed with a
modiﬁed Boyden-chamber assay. Endothelial cells are plated on top of
a ﬁlter with a deﬁned pore size and migrate through as a response to
an attractant in a lower chamber. The assay is highly sensitive to small
differences in concentration gradients [113–118].
Endothelial cells, including progenitor and immortalized cells,
rapidly form capillary-like structures in vitro when plated on top of a
basement membrane extracellular matrix [119]. The presence of ﬁbrin,
collagen or Matrigel stimulates the attachment, migration and differen-
tiation into capillary-like tubules in amanner thatmirrors the in vivo sit-
uation, and, to some extent, tissue architecture. Tube formation is
quantiﬁed from several microscopic ﬁelds randomly selected in a
given experiment, by measuring the total number of nodes, connected
and unconnected tubes as well as their lengths by digital images
produced by CCD cameras. These images are processed with a speciﬁc
digital image-analysis system for automated and quantitative
evaluation [120–123].
The second approach is based on direct detection of known factors
effecting tumor cell angiogenesis [124]. It employs monoclonal/poly-
clonal antibodies for known angiogenesis activators (e.g. members of
the VEGF, FGF, EGF family) by immunoblot or ELISA [125–127].
The key enzymes and regulators that allow the study of gene expres-
sion linked to angiogenesis are summarized in Table 6 [128–132].
2.5. Activating invasion and metastasis
The spread of neoplastic disease has been described as a sequential
multi-step process, termed the invasion-metastatic cascade. The pro-
gram by which epithelial cells acquire migratory and invasive capacity
is called epithelial-mesenchymal transition (EMT) [133]. The transfor-
mation includes the loss of cell adherence proteins, alteration of cell
morphology, increased motility, expression of matrix-degrading pro-
teinases and resistance to apoptosis, representing a fundamental
reprogramming of every aspect of the cell's biology. EMT, which is cen-
tral to normal developmental processes such as gastrulation [134], is
hijacked by cancer cells for their own dissemination. EMT can be in-
duced by intrinsic factors, such as genetic mutations, or by extrinsic sig-
nals, such as growth factors. However, some tumors exhibit incomplete
or partial EMT [135], or invade without epithelial–mesenchymal con-
version [136]. The tumormicroenvironment acquires increasing impor-
tance, as the crosstalk between the tumor and the surrounding stroma is
capable of inducing metastasis [137,138]. Understanding the complex
nature of interactions between cancer cells and the extracellular matrix
(ECM) requires a systems-based approach instead of focusingmerely on
genetic mutations within neoplastic cells.
Migration and invasion are distinct phenomena in experimental cell
biology. Migration is the directed movement of cells without passing
through obstructive barriers, whereas invasion necessitates the destruc-
tion of barriers in order to pass through them and thus is of necessity ac-
companied by ECM remodeling [139]. However, during both migration
and invasion, cells squeeze through tight interstitial spaces, and the nu-
clear deformation caused by the conﬁning microenvironment requires
subsequent restoration of the nuclear envelope and DNA content [140].
2.5.1. Transwell migration and invasion assay (Boyden chamber)
A double chamber is ﬁlled with two media, one with an attractant
(like FBS) to trigger chemotaxis. Cells are seeded in the upper well,
and migrate vertically between the chambers through a porous mem-
brane [141,142]. Migrated cells can be visualized by cytological dyes,
stained ﬂuorescent, or lysed and assessed by a plate reader. Due to dif-
ferent cell dimensions, the assay must be optimized for each cell type
[139]. By coating the porous ﬁlter with ECM components like type Icollagen or a basement membrane-like matrix (Matrigel), the device
is made suitable for testing invasion. Invasive cells degrade the matrix
and move through to the bottom. Parallel measurements with ECM-
coated and non-coated assays allow one to calculate an “invasive
index”: the rate of invasiveness versus migration [143]. Although pro-
viding only endpoint measurements, the transwell invasion assay is
the most frequently used method due to its easy setup.2.5.2. Scratch (wound healing) assay
This simple and popular assay allows the observation of two-
dimensional (2D) cell migration in conﬂuent, monolayer cell cultures.
The surface of a cellularmonolayer is wounded by scraping, and images
are captured bymicroscopy at regular intervals to track themigration of
cells from the edge of the wound until the scratch is closed [116,144,
145]. Time-lapse microscopy with image analysis software enables
automation. Mechanical scraping is done usually with pipette tips,
needles, razors, etc., although more advanced methods produce more
controllable wound sizes with clearly deﬁned edges, without damaging
the underlying matrix. Electric cell-substrate impedance sensing (ECIS)
systems enable automatic monitoring of cell adherence and wound
closure while ablating cells with a high electric current [146,147].
Laser ablation is another method to create a well-deﬁned scratch [148,
149], however both methods generate leftover cells and debris in the
wound area [150]. Dying cells release apoptotic factors, potentially
effecting wound closure. The advantage of the scratch assay is its easy
setup and low cost, but the experiments usually require relatively
large cell and reagent quantities. Scratch assays are appropriate to
study regeneration of epithelial or endothelial cells [116], and can be
combined with other techniques, such as gene transfections [151].2.5.3. Cell exclusion zone assays
Cell-free zones are created before seeding the cells, using a physical
barrier such as silicone. Later, the barrier is removed, allowing cells to
occupy the area [152]. Alternatively, cells are seeded inside of a ring,
and migrate outward once the barrier is removed [153]. Barriers can
be made of glass, silicone, metal, Teﬂon, microfabricated soft and elastic
“stencils” or agarose gels [139,150,153,154]. Cells are visualized by pho-
tomicrography or labeled with ﬂuorescence and measured with a mi-
croplate reader [150,152]. Migratory capacity and interaction between
two different populations can be compared [139]. These assays avoid
the drawbacks of scratch assays, such as uneven and irreproducible
scratch areas and remnants of dying cells in the media.2.5.4. Microcarrier bead and spheroid migration assays
Cells migrate from the surface of conﬂuent cell-coated microcarrier
beads to a 2D surface in a cell culture vessel, where cells can be ﬁxed,
stained and quantiﬁed. The close contact of cells on the bead surface
mimics in vivo cell-to-cell contact better than ﬂat monolayers [155].
The original version of the assay measures end-points, but cells can
also be traced duringmigration by lightmicroscopy [139]. Beads are ex-
pensive and some beads might not be covered sufﬁciently. In the spher-
oid migration assay, tumor cell spheroids are placed on a surface of
cultured vessels. Tumor cell spheroids resemble in vivo physiologic con-
ditions by establishing oxygen and nutrient gradients characteristic of
tumors, but the method can only be performed on cells that are able
to form spheroids [156]. The spheroid invasion assays enable the study
of invasive properties of multicellular spheroids embedded into three-
dimensional (3D) extracellular matrices [157]. Different scenarios in-
cludingmalignant andnon-malignant spheroids and invasion of epithe-
lial cells can be investigated [158,159]. In the spheroid confrontation
assay two cell types are co-cultivated, allowing them to invade each
other in a single cell pattern or collectively as a population [160]. Fluo-
rescent labeling enables an invasion to be followed with microscopy,
and ﬂow cytometry allows quantiﬁcation of invasive cells.
308 O. Menyhárt et al. / Biochimica et Biophysica Acta 1866 (2016) 300–3192.5.5. The capillary chamber migration assay
The capillary chamber migration assay consists of two chambers,
one containing the cell suspension and the other a chemoattractant,
connected by a linking capillary. Migratory behavior of cells is observ-
able, and morphological responses are visualized by time-lapse micros-
copy in real time [161]. The small cell numbers and reagent volumes
make this assay suitable for rare cell types and expensive compounds.
Liquid handling and image processing can be fully automated [162].
2.5.6. Vertical assays
Cells are placed on top of an ECM, where after forming a monolayer
they move down individually or collectively, as ﬁrst described with
lymphocytes [163]. In skin cancer, cells can also be coated with matrix
and move up [164,165]. Alternatively, cell monolayers can be
sandwiched between a top and bottom layer of ECM, and additional
cell types might be embedded into the ECM to study their effects on
cell invasion [166].
2.5.7. Motility of individual cells
Motility of individual cells can be traced by time-lapse video
microscopy. New algorithms are available to follow up to a dozen cells
simultaneously [167]. 3D tracking is also possible, but requires special-
ized microscopes and image analyzing software, as well as extensive
data processing [168]. The gelatin degradation assay allows analysis of
progressive invasion at a subcellular level. The ability to form
invadopodia directly correlates with the invasive potential of tumor
cells. Cells are seeded on top of a thin, ﬂuorescent dye-labeled gelatin
matrix. The actin-rich invadopodia and podosomes extend into the
ECM and degrade the gelatin with matrix metalloproteinases, creating
spots with decreased ﬂuorescence [169]. Computerized methods allow
the analysis of invasive properties of single cells as well as of popula-
tions [170].
2.5.8. Mechanical properties
Mechanical properties of individual tumor cells affect the way cells
are able to spread. Metastatic cancerous cells are 70% less stiff than nor-
mal cells [171], and stiffness inversely correlates withmigration and in-
vasion through 3D structures, measured by a magnetic tweezer system
combinedwith a 3DMatrigel invasion assay [172]. A recently developed
high throughputmicroscope system is able to assess cellularmechanical
properties in multiwell plates [173].
2.5.9. Real-time monitoring and live-cell imaging
The impedance based xCELLigence System (see also Section 2.1.5)
permits label-free real-time monitoring of invasion and migration.
Membranes can be coated with ECM to study invasive properties [174].
The IncuCyte™ Chemotaxis System, based on live-cell time-lapse
imaging, allows automated visualization of labeled or label-free chemo-
tactic cell migration and invasion even in multiwell format [175,176].
The most frequently used in vitromigration and invasion assays are
summarized in Table 4, and the genes linked to migration and invasion
are summarized in Table 6 [157,167,177–180].
2.6. Genome instability and mutation
Most cancers exhibit chromosomal instability, meaning altered
chromosomal structures and high rates of rearrangements compared
to normal cells. Microsatellite instability is characterized by the expan-
sion or reduction of short nucleotide repeats present in microsatellite
sequences. Nucleotide instability refers to the increased frequency of
substitutions, deletions and insertions in one or several nucleotides
[181]. The origin of genomic instability is still a subject of intense re-
search [182]. Oncogene activation can induce the collapse of DNA repli-
cation forks resulting in double-strand breaks. DNA damage activates
TP53, leading to senescence or apoptosis. In contrast, inactivating
(loss-of-function) mutations in TP53 eliminate the barrier againsttumor progression [183]. In hereditary cancers, loss of a DNA repair
gene is considered to drive cancer development by increasing the spon-
taneous mutation rate [182]. Neoplastic cells incur mutations through
increased sensitivity to mutagens, by weakening the genomic mainte-
nance machinery or by eliminating the surveillance system guarding
genomic integrity.
2.6.1. Flow cytometry
Flow cytometry is a universal multicellular approach that can detect
cellular ploidy and cell cycle distributionwith ﬂuorescent dyes that bind
to DNA in stoichiometric fashion. Genome instability can be evaluated
by comparing ploidy in the G0/G1 fraction for tumor versus normal
cells. However, ﬂow cytometry does not provide information about
other levels of genome instability [184].
2.6.2. Karyotyping
Karyotyping is a more informative method. A DNA-binding dye in-
tercalates into speciﬁc DNA regions of chromosomes (e.g. A/T-rich
areas) in metaphase spreads, resulting in a speciﬁc banding pattern
for each chromosome. Spectral karyotyping is a multicolored whole
chromosome-painting assay using FISH probes to visualize each chro-
mosome. Decoding the chromosomes with different ﬂuorochromes al-
lows speciﬁcation of rearrangements by confocal microscopy. Spectral
karyotyping is limited to detecting global changes in chromosomes
and as such is unable to evaluate alterations at the sequence level
[185,186].
2.6.3. Array of comparative genomic hybridization
Array of comparative genomic hybridization (aCGH) is a multicellu-
lar technique used to quantitatively detect and visualize chromosomal
alterations. For the detection of gains, losses, ampliﬁcations and loss-
of-heterozygosity, the sample DNA is compared to a normal reference
genome. The differentially-labeled reference and sample DNAs are com-
bined, and non-analogous hybridizations are visualized as changes in
ﬂuorescence intensity on metaphases. CGH detects unbalanced chro-
mosomal abnormalities affecting copy number, but is unable to distin-
guish reciprocal translocations, inversions or somatic mutations [187,
188]. Single nucleotide polymorphism (SNP) arrays are also
hybridization-based. Fragmented nucleic acid sequences labeled with
ﬂuorescent dyes hybridize to immobilized, allele-speciﬁc oligonucleo-
tide probes. SNP arrays are capable of detecting copy-neutral loss of het-
erozygosity (so-called uniparental disomy or gene conversion) and
distinguish alleles at speciﬁc polymorphic sites [189].
To detect microsatellite instability (MSI), the gold standard ap-
proach ampliﬁes known microsatellite regions by PCR and quantiﬁes
the lengths of PCR products by gel or capillary electrophoresis using au-
toradiography, silver staining [190] or ﬂuorescent methods [191,192].
The microsatellite length of the sample is compared to normal DNA to
determine MSI status. Alternatively, real-time quantitative PCR (qPCR)
melting point analysis is used with sequence-speciﬁc ﬂuorescent-
labeled hybridization probes [193]. MSI status can also be detected
with next generation DNA sequencing (NGS) [194]. Microsatellite insta-
bility is the results of defects in mismatch repair (MMR) genes such as
MSH, MLH and PMS: the expression proﬁle of MMR genes correlates
with microsatellite instability [193]. Mutant MMR genes are translated
to proteins, andmutantMMRproteins can be studied by immunochem-
istry using mutation-speciﬁc monoclonal antibodies [195].
2.6.4. Whole genome sequencing
Whole genome sequencing is themost comprehensive and informa-
tive method to distinguish nucleotide mutations in coding, non-coding
and un-annotated regions. It is also able to measure larger genomic re-
arrangements frequently present in cancer such as copy number varia-
tions (CNV), insertions and translocations [196]. Sanger sequencing,
developed in 1977, is based on a dideoxy chain-termination method
and provides high-quality, long read length, spanning 400–900 base
Table 4
Comparison of migration assays and their modiﬁcations into invasion tests.
Migration assay features Cell type Direction of
movement
Chemokine
gradient
HTS Equipment
complexity
Individual cell
tracking
Data collection methods Analysis type Modiﬁcation to invasion
assay
Transwell migration assay
(Boyden chamber assay)
[141,142]
Adherent cells Vertical ✔ ✔ Chambers Easy setup – Cell counting Fluorescent
staining
Endpoint Coating chamber with ECM
[143]
Scratch (wound healing)
assay
[116,144,147,149]
Adherent cells Horizontal – ✔ Plastic or glass surface Easy
setup
✔ Cell counting with
time-lapse
microscopy
Kinetic –
Cell exclusion zone and fence
assays [150,152–154,275]
Adherent cells Horizontal – ✔ Plastic or glass surface
Physical
barrier Easy setup
✔ Cell counting with
microscope
Fluorescent staining
Kinetic Coating the surface with
ECM
(Platypus invasion assay)
[276]
Microcarrier bead assay
[155] and
Spheroid migration assay
[156]
Adherent cells /
Spheroid
Vertical and
horizontal
– ✔ Plastic or glass surface
microbeads
technically demanding
✔ Cell counting with
microscope
ﬂuorescent staining
time-lapse microscopy
Endpoint/kinetic Microbeads or spheroids
placed into ECM
[157,158,160]
Capillary migration assay
[161,162]
Adherent and
suspension
cells
Horizontal ✔ ✔ Glass surface Speciﬁc
chambers
Technically demanding
– Cell counting with
microscopy
Endpoint /
kinetic
–
Single cell motility assay
[167,277–279]
Adherent and
suspension
cells
Horizontal ✔ ✔ Glass surface Advanced
Expensive technical setup
✔ Cell tracking with time-lapse
microscopy
Kinetic Coating the surface with
ECM [163]
Gelatin degradation assay
[169]
Adherent cells Vertical – – Gelatin media – Cell tracking with
microscopy
Endpoint Coating the surface with
ECM
Mechanical properties
(stiffness,
compliance) [172,173]
Adherent cells Horizontal – ✔ 3D Force Microscope, coated
magnetic beads
– high speed video camera,
video
spot tracker
Endpoint Only for invasion
xCELLigence System [174] Adherent cells Horizontal – ✔ (16
well
plate)
Speciﬁc chambers – Microelectronic cell sensor Kinetic Coating chamber with ECM
[174]
IncuCyte™
[176]
Adherent and
non-adherent
cells
Horizontal ✔ ✔ Speciﬁc chambers, Costly
initial set up
✔ Live-cell time- lapse imaging Kinetic Coating chamber with ECM
[175]
Abbreviations: HTS: high throughput screening, ECM: extracellular matrix.
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Next-generation sequencing (NGS) systems enable high throughput
and accurate analysis along with decreased sequencing cost. The
Illumina GS/HiSeq platform implements sequencing by synthesis tech-
nology providing high throughput and low reagent cost; nevertheless
it is hampered by short read lengths. The Ion Torrent adopts semicon-
ductor sequencing and provides rapid and low-cost sequencing results
[197]. Sequencing the transcriptome (RNA-seq) also allows the discov-
ery of special genetic aberrations, such as gene fusions; it could replace
microarrays in the long run [198]. Developments in NGS and whole-
genome ampliﬁcation already allow single-cell sequencing [199,200].
Adequate genome coverage is critical, and each area of genome research
requires markedly different sequencing depth [201].
Commonmethods to assess genomic instability and their association
with hallmark features are illustrated in Fig. 1C. Genes participating in
genomemaintenance and related to cancer genome instability are listed
in Table 6 [202,203].
2.7. Reprogramming energy metabolism
Actively proliferating cancer cells must regulate their energymetab-
olism to fuel constant cell growth. By simultaneously increasing the rate
of glycolysis while limiting oxidative phosphorylation, cells enter a state
termed aerobic glycolysis, also known as the Warburg effect [204,205].
Increased glycolysis can allow the diversion of glycolytic intermediates
into biosynthetic pathways required for new cell assembly. Altered en-
ergymetabolism is sowidespread in cancer cells that it has been includ-
ed as one of the hallmarks of cancer [206].
2.7.1. Glucose uptake
Glucose is rapidly metabolized, so virtually non-metabolizable glu-
cose analogs like FDG (ﬂuoro-deoxyglucose), 2DG (2-deoxy-D-glucose)
and 3MG (3-O-methylglucose) are needed to study uptake efﬁciency. In
cell cultures, the most commonly used analogs are radioactive hexoses,
quantiﬁed from cell lysates by a liquid scintillation counter [207–209].
The uptake of nonradioactive, ﬂuorescent glucose analogs is measured
by ﬂow cytometry or ﬂuorescence microscopy [210]. Enzymatic assays
of glucose uptake are based on a dye reduction reaction connected to
the ﬁrst step of glycolysis and are detected spectrophotometrically
[211,212].
2.7.2. Activity of rate-limiting glycolytic enzymes
Hexokinase, phosphofructokinase, and pyruvate-kinase are the
main rate-limiting enzymes of glycolysis, controlling the maximum
possible carbon ﬂux. Enzyme activity is assessed by coupling them
with a NAD+/NADH- dependent enzyme reaction producing visible
substrates andmeasuring changes in absorbance values [213]. Determi-
nation of free nuclear NADH can be assessed by two-photonmicroscopy
to quantify the intensity of NAD(P)H autoﬂuorescence.
2.7.3. Metabolomics and inorganic products
Metabolites are quantiﬁed by mass spectroscopy (MS) or nuclear
magnetic resonance spectrometry (NMR). By using 13C- or 3H-labeled
glucose, the amount of 13C- or 3H-glucose derived isotopes in down-
stream metabolites is linked to glycolytic activity. 13C can replace any
of the six carbons in the glucose molecule [214]. 3H is incorporated
into H2O from a 3H-labeled glucose [215]. 3H2O is released into the me-
dium by the conversion catalyzed by enolase and its subsequent pres-
ence in the media of cultured cells can be measured by liquid
scintillation counting [216].
2.7.4. Oxygen consumption
The rate of oxygen consumption (OCR) is a universal indicator of
mitochondrial respiration, and can be measured both intra- and
extracellularly. Intracellular O2-levels provide accurate information
about the metabolic activity of a cell. The measurement is based on acell-penetrating O2-sensitive phosphorescent probe [217]. Currently,
supramolecular and nanoparticle-based intracellular probes are
available with rapid intracellular accumulation allowing direct,
contact-free and quantitative oxygen assessment. The assays are
typically performed in microplates and measured by real-time
ﬂuorescence plate readers [218].
Extracellular oxygen consumption can bemeasured by polarograph-
ic respirometry (Clark's electrode) or with optical sensor probes. A
Clark's electrode allows measurement of intact cells or extracted
mitochondria in suspension by polarography [219]. Optical sensor
probes determine oxygen consumption from themedium over amono-
layer of living cells within a microplate reader. The Extracellular Flux
Analyzer measuresmultiple metabolic parameters, such as oxygen con-
sumption rate (OCR) and extracellular acidiﬁcation rate (ECAR) in real
time. Metabolism can also be modiﬁed by successive addition of differ-
ent compounds [220]. Duringmitochondrial stress, the sequential addi-
tion of metabolic modulators to different parts of the electron transport
chain (Fig. 2A) allows the identiﬁcation of key mitochondrial parame-
ters such as basal respiration, ATP turnover, proton leak and maximal
respiration. The difference between maximal and basal respiration
represents the respiratory reserve, the capacity of a cell to create ATP
via oxidative phosphorylation in response to increased energy demand.
Non-mitochondrial respiration results in substrate oxidation and cell
surface oxygen consumption (Fig. 2B).
2.7.5. Extracellular acidiﬁcation
Intensiﬁed glycolysis with higher glucose uptake results in excess
lactate secretion into the extracellular environment. Commercially
available kits are available to quantify lactate levels in cell cultures and
are based on colorimetric or ﬂuorometric reactions compatible with
standard laboratory equipment, e.g. spectrophotometers [221,222].
Glycolytic activity is also indicated by conversion of pyruvate to lactic
acid, determining the extent of extracellular acidiﬁcation rate (ECAR)
as measured by an extracellular ﬂux analyzer [223]. This test is
performed by adding glucose, followed by inhibitors of glycolysis and
oxidative phosphorylation, and provides information on glycolytic
capacity and reserve. Glycolytic reserve indicates the cell's ability to
increase glycolytic rate upon increased energy demand (Fig. 2C).
2.7.6. Glutathione (GSH)
Glutathione (GSH) is a tissue antioxidant preventing cell damage
from free radicals and peroxidases. Increased levels of oxidative stress
generate oxidized glutathione (GSSG), causing an increased ratio of
GSSG to GSH. Increased susceptibility to oxidative stress has been impli-
cated in cancer development [224]. Alterations in the GSH molecular
pathways in cancer cells can lead to enhanced chemoresistance and
increased survival. Tumor glutathione levels tend to be altered, i.e.
frequently increased compared to healthy tissue [225]. GSH and GSSG
levels can be assessed rapidly and reliably spectrophotometrically in a
microplate reader [226].
Assays of energy metabolism are summarized in Table 5, and their
connection with hallmark features are illustrated in Fig. 1D. Expression
of glucose transporters or other metabolic enzymes is rendered feasible
by immunoblotting, FACS or qPCR. The bioenergetics andmetabolism of
a cell can also be estimated by analyzing gene expression of key en-
zymes (Table 6) [227,228].
2.8. Epigenetics
In recent years, epigenetics has become equally important compared
to genetic mechanisms in cancer initiation and progression [229,230].
Promoter hypermethylation leads to transcriptional silencing. CpG
methylation represents a key epigenetic mechanism of inactivation of
tumor suppressors and MMR genes [231]. Methylation patterns can be
detected by methylation-speciﬁc PCR (MSP). Treating the DNA with
sodium bisulﬁte converts unmethylated cytosine to uracil, and during
Fig. 2. Schematic representation of measured features related to the reprogramming of energy metabolism. Inhibitors used during OCR and ECARmeasurements (A). Schematic graph of
OCR illustrating metabolic modulators and the detected key parameters (B). Schematic graph of ECAR measurement. (C). Blue arrows represent glycolysis. Blue box represents Electron
Transport Chain (ETC)members in themitochondrial innermembrane: Complex I: NADHdehydrogenase, Complex II: Succinate dehydrogenase, Q: CoenzymeQ, Complex II: CoenzymeQ,
cytochrome-c oxidoreductase, Complex IV: cytochrome-c oxidase, ComplexV:ATP synthase. Black arrows represent electronﬂow in themitochondrial ETC. Inhibitor abbreviations: 2-DG:
2-deoxyglucose, FCCP: triﬂuorocarbonylcyanide phenylhydrazone. Oligomycin is an ATP synthase inhibitor, blocks the mitochondrial respiration and pushes the cells to rely upon
glycolysis for ATP production. DNP or FCCP are mitochondrial uncouplers that compel the mitochondria to raise the ﬂow of electrons and oxygen consumption. Antimycin A &
rotatone block complexes in the electron transport chain of mitochondria. Other abbreviations: TCA cycle: tricarboxylic acid cycle, Acetyl-CoA: acetyl coenzyme A, cyt c: cytochrome c,
ATP: adenosine triphosphate, ADP: adenosine diphosphate, H+: proton. The parameters measured with extracellular ﬂux analyzer, the rate of oxygen (O2) consumption and the
measure of protons (H+) released during lactate production, are depicted in green boxes.
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the unmethylated sequence [232]. MSP is not quantitative and bears a
signiﬁcant risk of false positive and false negative results. In contrast,
Quantitative Methylation-Speciﬁc PCR (qMSP) assays utilizing TaqMan
probes are highly sensitive to promoter hypermethylation and available
in high throughput format (e.g. MethyLight) [233]. Quantitative multi-
plex methylation-speciﬁc PCR (QM-MSP) accurately determines pro-
moter hypermethylation for many genes simultaneously in small
samples, is highly sensitive and linear over 5 orders of magnitude
[234]. Pyrosequencing is a “sequencing by synthesis” technique, during
which nucleotide incorporation releases a pyrophosphate molecule,
generating a luciferase-catalyzed luminometric signal. Pyrosequencing
can be used for quantiﬁcation of DNA methylation at speciﬁc CpG sites
within the target region [235]. Themethod provides high quality, quan-
titative results and is appropriate to analyzemethylation of CpG sites in
close proximity [236]. DNAmethylation enrichment methods avoid the
limitations of bisulﬁte-conversion. Methyl-CpG binding domain-based
capture (MBDCap) uses beads coated in MBD polypeptide that bind
methylated DNA; the eluted DNA is sequenced with NGS [237,238]. In
addition, epigenetic studies employ chromatin immunoprecipitation(ChIP) to identify DNA sequences that are associated with a chromatin
component of interest. Coupled with high-throughput methods, such
as microarrays (ChIP-chip) or massively parallel sequencing (ChIP-
seq) it is possible to identify binding sites of speciﬁc proteins across
the entire genome [239,240].
Small (17–24 base), highly conserved, non-coding microRNAs
(miRNA) regulate gene expression at the post-translational level by
targeting complementary mRNAs and play a regulatory role in all cellu-
lar pathways [241]. About half of all miRNA genes are located in close
proximity to CpG islands and thus are subject to epigenetic regulation
via DNA methylation and chromatin remodeling. Additionally, miRNAs
modulate the expression of genes linked to the epigenetic machinery
[242]. Disregulated miRNA expression has been connected to cancer
initiation and progression [243]. Microarray hybridization, quantitative
reverse transcription PCR (RT-qPCR) and small RNA sequencing with
NGS are the most common platforms to evaluate miRNA expression,
although the small size of active, mature miRNAs renders expression
proﬁling challenging. Comparing reproducibility, speciﬁcity, sensitivity
and accuracy across 12 commercially available platforms showed
qPCR in general to be especially suitable for low input RNA samples
Table 5
Comparison of assays suitable for measuring altered energy homeostasis.
Energy metabolism features Target of analysis Method Detection Principles Advantages /disadvantages
Glucose uptake Labeled glucose Stable isotope tracking
analysis
Liquid scintillation counter [207–209] Radioactive hexoses e.g.: 2-deoxy-D-[1,2-3H]-glucose
or 2-deoxy-D-[1-14C]-glucose
Better signal-to-noise ratio and higher
speciﬁcity.
Expensive and requires specialized
training and equipment
Fluorescent hexose analogs
tracking analysis
Flow cytometry, ﬂuorescence microscopy
[210]
Fluorescent glucose analogs:
2-[N-(7-nitrobenz-2-oxa-1,3-diaxol-4-yl)amino]-
2-deoxyglucose (2-NBDG)
Single cell analysis
Glucose analog
conversion
Enzymatic assay for glucose
determination
Spectrophotometric method [211,212] 2DG-P converted to 2-deoxy-6-phosphogluconate by
G6PDH parallel with NADP+ reduction, coupled with dye
conversion to ﬂuorescent form (resazurin to resoruﬁn)
Simple technique
Hexose conversion Phenotype MicroArrays™ Spectrophotometric method [280] Added monotype carbon nutrients, detection of NADH
production by redox dye alteration
Parallel testing of several
metabolic pathways
Rate-limiting glycolytic
enzymes
Activity of glycolytic
enzymes
Measuring activity of
rate-limiting
glycolytic enzymes
Spectrophotometric method [213] Glycolytic enzyme reaction coupled with NAD+/NADH-
or NADP+/NADPH-dependent enzymes
by using enzymes that react with their products.
Simple technique
Metabolic results Metabolites from
glucose
Metabolomics Mass spectroscopy (MS)
nuclear magnetic resonance
spectrometry (NMR)
[214]
13C or 3H-labeled glucose derived isotopes in
downstream metabolites
NMR spectroscopy is fast,
quantitative and reproducible,
but MS is more sensitive. MS
needs metabolite separation
by chromatography.
H2O Stable isotope tracing Liquid scintillation counter [215,216] Trace of 3H from 3H-labeled glucose to H2O from media The labeled glucose must be
removed from the sample
Oxygen consumption Intracellular O2 level Intracellularoxygen-sensitive
probes
Spectrophotometric method [217,218] Cell-penetrating O2-sensitive phosphorescent probes
Extracellular O2 level Clark's electrode Polarography [219] Oxygen dissolved in liquid or gas phase in the sample
chamber is detected by polarography using a
Clark-type oxygen electrode
Large amount of material, isolated
mitochondria and permeabilized cells
Extracellular O2 level XF Extracellular Flux
Analyzer
Spectrophotometric method [223] The dissolved oxygen is measured by solid state
ﬂuorophore probes.
Inhibitors: oligomycin, DPN or FCCP,
and antimycin A & rotenone
Extracellular
acidiﬁcation
Extracellular lactate
level
Lactate assay Spectrophotometric method [221,222] Lactate in the media is oxidized by added LDH to
generate a substance which interacts with a
probe to produce a color/ﬂuorescent signal
Simple technique
Extracellular pH/lactate
level
XF Extracellular Flux
Analyzer
Spectrophotometric method [223] The pH in cell media is measured by solid state
ﬂuorophore probes.
Oxidative stress Glutathione Measuring GSH/GSSG
ratio
Spectrophotometric method [226] Enzymatic recycling of GSH from GSSG by glutathione
reductase. GSH reacts with DTNB producing
TNB chromophore.
Simple technique
Abbreviations: 2DG-P: 2-deoxy-D-glucose phosphate, DPN: dinitrophenol, FCCP: triﬂuorocarbonylcyanide phenylhydrazone, GAPDH: glucose-6-phosphate dehydrogenase, DTNB: 5,5′-dithio-bis(2-nitrobenzoic acid).
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Table 6
List of marker genes for which an expression change is linked to a hallmark feature.
Hallmark feature Marker genes
Sustaining proliferative signaling and evading growth suppressors [39,40]
Oncogenes BAX, BCL2L1, CASP8, CDK4, ELK1, ETS1, HGF, JAK2, JUNB, JUND, KIT, KITLG, MCL1, MET, MOS, MYB, NFKBIA, NRAS, PIK3CA, PML, PRKCA,
RAF1, RARA, REL, ROS1, RUNX1, SRC, STAT3, ZHX2
Tumor suppressor genes ATM, BRCA1, BRCA2, CDH1, CDKN2B, CDKN3, E2F1, FHIT, FOXD3, HIC1, IGF2R, MEN1, MGMT, MLH1, NF1, NF2, RASSF1, RUNX3, S100A4,
SERPINB5, SMAD4, STK11, TP53, TP73, TSC1, VHL, WT1, WWOX, XRCC1
Transcriptional factors ABL1, BRCA1, BRCA2, CDKN2A, CTNNB1, E2F1, ELK1, ESR1, ETS1, FOS, FOXD3, HIC1, JUN, JUNB, JUND, MDM2, MEN1, MYB, MYC, MYCN,
NF1, NFKB1, PML, RARA, RB1, REL, RUNX1, RUNX3, SMAD4, STAT3, TGFB1, TNF, TP53, TP73, TSC1, VHL, WT1, ZHX2
Cell cycle ATM, BRCA1, BRCA2, CCND1, CDK4, CDKN1A, CDKN2A, CDKN2B, CDKN3, E2F1, HGF, MEN1, STK11
Multiple features BCR, EGF, ERBB2, ESR1, FOS, HRAS, JUN, KRAS, MDM2, MYC, MYCN, NFKB1, NRAS, PIK3C2A, RB1, RET, SH3PXD2A, TGFB1, TNF, TP53
Resisting cell death [75,76]
Apoptotic pathway members
Bcl2 Family-regulated pathway BCL2, BCL2L1, BCL2L2, BCL2L10-15, MCL1, BAX, BCL2A1, BAK1, BAD, BOK, BBC3, BIK, BNIP3L, HRK, BBC3, BID, BNIP3
TNF Receptor pathway TNFRSF1A, TNFRSF1B, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10, TNFRSF11, TNFRSF21, NGFR, TRAF1, TRADD
TNF superfamily TNF, TNFSF4, TNFSF8-15, LTA, LTB
Fas signaling pathway (CD95) FAS, FASLG
Caspase family CASP1 (ICE), CASP10 (MCH4), CASP14, CASP2, CASP3, CASP4, CASP5, CASP6, CASP7, CASP8, CASP9, CFLAR (CASPER), CRADD, PYCARD
(TMS1/ASC),
NF-kß signaling pathway NFKB1, NFKB2, NFKB3, NFKBIB, NFKBIA, NFKBIE, NFKBIKB, RELB, NFKBIZ, REL, IKBKE
IAP family DIABLO
CARD family APAF1, BLC10, RIPK2, BIRC1-8, CRADD, CARD4-19, NALP1, PYCARD
Kinases TBK1, DAPK1, CHUK
Other NOXA, SOCS3, DEDD, DEDD2, PEA15, DAXX, FADD
TP53 pathway
TP53 activators ATM, ATR, BBC3, BRCA1, CDKN1A (p21CIP1/WAF1), CDKN2A (p16INK4), CHEK1, CHEK2 (RAD53), FOXO3, GML, MDM2, MSH2, SIRT1,
TP63, TP73
TP53 regulators and cooperators CDKN2A (p16INK4), DNMT1, HDAC1, KAT2B, MDM2, MDM4, SIRT1, TADA3, TP53AIP1, TP53BP2, TP63 (TP73L), TP73
Apoptosis pathway members APAF1, BCL2, BCL2A1, BID, BIRC5, CASP2, CASP9, CRADD, FADD, FASLG (TNFSF6), IGF1R, MCL1, NF1, NFKB1, PIDD (LRDD), RELA,
TNFRSF10D, TRAF2, WT1
Cell cycle pathway members CCNB1, CCNE1, CCNG1, CCNH, CDK1 (CDC2), CDK4, PRC1, TSC1
DNA repair pathway members BRCA2, MLH1, XRCC5
Transcriptional factors BRCA2, EGR1, JUN, MYOD1, NFKB1, RELA, STAT1
Enabling replicative immortality [101,102,105–107]
Telomere maintenance
ACD, BLM, DCLRE1C, DKC1, ERCC1, ERCC4, HSPA1L, MRE11A, MYC, NBN (NBS1), PARP1 (ADPRT1), PIF1, POT1, PRKDC, PTGES3, RAD50,
RFC1, RTEL1, SMG6, TEP1, TERF1, TERF2, TERF2IP, TERT, TINF2, TNKS (TIN1), TNKS2, XRCC5, XRCC6 (G22P1)
Regulation of telomere length RTEL1, TEP1, TERF1, TERF2IP, TNKS (TIN1)
Telomerase activity
Telomerase complex DKC1, GAR1, NHP2, NOP10, TERT, WRAP53, hTR, NOLA1-3, ACD, POT1, RAP1A, TERF1, TERF2, TINF2, SLX4, ERCC1, ERCC4, EME1, MSH2,
MSH3, MUS81, PLK1, TERF2, TERF2IP
Telomerase regulation BL1, AKT1, ATP5C1, BCL2, EGF, IGF1, KRAS, MEN1, MYC, PAX8, PINX1, PPARG, PPP2R1A, PPP2R1B, PRKCA, PRKCB, RB1, SART1, SMAD3, SP1,
SSB, TGFB1, TP53, MAD1L1, MEN1, SIP1,
Senescence pathways
ATM, BMI1, CCND1, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKN2A (p16INK4), CDKN2D, CHEK1, CHEK2, E2F1, E2F3, ETS1, ETS2, MDM2,
RB1, RBL2, TP53, TWIST1
Senescence secretome
Soluble factors IL-6, IL-7, IL-I, IL-13, IL-15
Chemokines IL-8, GRO, MCP-2, MCP-4, MIP-1, MIP-3, HCC-4, EOTAXIN, TECK, ENA-78, I-309, I-TAC,
Inﬂammatory factors GM-CSE, G-CSE, IFN-ƴ, BLC, MIF
Growth factors Amphiregulin, eporegulin, heregulin, EGF, Bfgf, HGF, KGF, VEGF, angiogenin, SCF, SDF-1, PIGF, NGF, IGFBP-2-7
Protease, regulators MMP-1,-3,-10,-12,-13,-14, TIMP-1,-2, PAI-1,-2, tPA, uPA, Cathepsin B
Soluble or shed receptors or ligands ICAM-1,-3, OPG, sTNFRI, TRAIL-R3, Fas, sTNFRII, uPAR, SGP130, EGF-R
Nonprotein soluble factors PGE2, nitric oxide
Insoluble factors (ECM) Fibronectin, collagens, laminin
Inducing angiogenesis [128–132]
Growth factors and receptors ANG, ANGPT1, ANGPT2, ANPEP, TYMP, FGF1, FGF2 (bFGF), FIGF (VEGFD), FLT1, JAG1, KDR, NRP1, NRP2, PGF, VEGFA, VEGFB, VEGFC,
Proteases, inhibitors and other
matrix proteins
ANGPTL4, F3, PECAM1, PF4, PROK2, SERPINE1 (PAI-1), SERPINF1,
Adhesion molecules BAI1, COL4A3, IL8, NRP1, NRP2
Cytokines and chemokines BMP2, CCL15, CCL2, CSF3, CXCL11, CXCL12, CXCL13, CXCL14, CXCL3, CXCL5, CXCL6, CXCL9, IL10, IL6, IL8, PPBP, PTN, TNF
Other HIF1A, NOS3, SPHK1, AGGF1, AMOT, ANG, ANGPT1, BTG1, EDIL3, EREG, FST, RHOB, RUNX1
Activating invasion and metastasis [157,167,177–180]
EMT transcription factors
Cell motility
SNAI1, SNAI2, SNAI3, TWIST1, TWIST2, FOXOC2, TCF3, SMAD3, HIF1A, TGFB1, ZEB2, ZEB1
Chemotaxis FGF2, ITGB2, MAPK1 (ERK2), MYH10, MYH9, PLAUR (uPAR), PLD1, PRKCA, RAC2, TGFB1, VEGFA, WASF2, WIPF1,
Receptors EGFR, IGF1R, ITGA4, ITGB1, ITGB2, ITGB3, MET, PLAUR (uPAR), RHO
Growth factors CSF1 (MCSF), EGF, FGF2, HGF, IGF1, TGFB1, VEGFA
Cell–cell adhesion DPP4, EGFR, EZR, ITGA4, ITGB1, ITGB2, MSN, MYH9, ROCK1, TGFB1,
Cell–matrix adhesion ACTN1, ACTN3, CSF1 (MCSF), ILK, ITGB1, ITGB2, ITGB3, MMP14, PTEN, PTK2B, PXN, RASA1, RHOA,
Focal adhesion ACTN1, ACTN3, ARHGEF7, BCAR1, CAPN1, CAPN2, CAV1, ENAH, ILK, ITGB1, MYL9, PTK2, PTK2B, PXN, TLN1, VASP, VCL
(continued on next page)
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Table 6 (continued)
Hallmark feature Marker genes
Proteolysis AKT1, CAPN1, CAPN2, DPP4, FAP, HGF, MMP14, MMP2 (Gelatinase A), MMP9 (Gelatinase B), MYH9, PLAUR (uPAR), TIMP2
Filopodia BAIAP2, CDC42, DIAPH1, EGFR, ENAH, EZR, MSN, RDX, SVIL, VASP,
Lamellopodia CTTN, DPP4, EGFR, ENAH, FAP, PIK3CA (p110a), PLD1, PTK2, PXN, RDX, SVIL, VASP, VCL, WASF1, WASF2, WASL
Invasive projections ACTR2, ACTR3, ARF6, CDC42, CFL1, CTTN, DPP4, EGF, EZR, FAP, MMP14, MMP2 (Gelatinase A), MMP9 (Gelatinase B), MSN, MYH9, PLAUR
(uPAR), RAC2, RASA1, SH3PXD2A, SRC, SVIL, TGFB1, VEGFA, WASL, WIPF1
Rho family GTPases
Rho signaling ACTR2, ACTR3, ARHGDIA, LIMK1, MSN, MYL9, MYLK, PLCG1, PLD1, PRKCA, PTEN, PTPN1, RHO, RHOA, RHOB, RHOC, RND3, ROCK1, VIM,
Rac signaling ACTR2, ACTR3, BAIAP2, CFL1, CRK, PAK1, PAK4, PLD1, PRKCA, RAC1, RAC2, STAT3, WASF1, WASF2, WASL,
Cdc42 signaling ACTR2, ACTR3, CDC42, PFN1, WASF1, WASF2, WASL
Invasion
Matrix metalloproteases MMP10, MMP11, MMP13, MMP2, MMP3, MMP7, MMP9
Transcription factors, regulators,
Other
CHD4, ETV4, EWSR1, HTATIP2, MTA1, MYC, MYCL, NR4A3, RB1, RORB, SMAD2, SMAD4, TCF20, TP53, CST7, CTSK, CTSL, CD82 (KAI1),
KISS1, METAP2, NME4,
Genome instability [202,203]
Cell cycle check point genes ATM, ATR, ATRIP, BARD1, BRCA1, CDC25A, CHEK1, CHEK2 (RAD53), CSNK2A2, FANCD2, H2AFX, HUS1, MDC1, PARP1 (ADPRT1), RAD1,
RAD17, RAD50, RAD9A, RBBP8, RNF168, RNF8, SMC1A, TOPBP1, TP53
Nucleotide excision repair ATXN3, BRIP1, CCNH, CDK7, DDB1, DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6, ERCC8, LIG1, MMS19, PNKP, POLL, RAD23A,
RAD23B, RPA1, RPA3, SLK, XAB2, XPA, XPC
Base excision repair APEX1, APEX2, CCNO, LIG3, MPG, MUTYH, NEIL1, NEIL2, NEIL3, NTHL1, OGG1, PARP1, PARP2, PARP3, POLB, SMUG1, TDG, UNG, XRCC1
Mismatch repair MLH1, MLH3, MSH2, MSH3, MSH4, MSH5, MSH6, PMS1, PMS2, POLD3, TREX1
Double strand break repair BRCA1, BRCA2, DMC1, FEN1, LIG4, MRE11A, PRKDC, RAD21, RAD50, RAD51, RAD51C, RAD51B, RAD51D, RAD52, RAD54L, XRCC2, XRCC3,
XRCC4, XRCC5, XRCC6
DNA replication checkpoint genes BL1, CDC6, MCM2, MCM3, MCM4, MCM5, WEE1
Mitotic phase checkpoint genes AURKB, CCNB2, CCNF, CDC25C, CDC6, CDK1 (CDC2), CDC16, CDC20, MRE11A, RAD51, STMN1
DNA repair AIMP2, APEX1, CHEK1, MSH2, NBN, NPM1, PCNA, TERT, TP53, BRCA1, BTG2, EGFR, GADD45A, PCNA, PTTG1, BRCA2, MLH1, XRCC5
Histone acetylation KAT5, NCOA1, NCOA3, KAT2B
Histone deacetylation HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7
Chromatin modiﬁcation molecules ESR1, NCOA6, PPARGC1B, CBX3, NAP1L1
Other ATM, ATR, ATRIP, ATRX, BARD1, BRIP1, CHEK2 (RAD53), CIB1, CRY1, EXO1, FANCA, FANCD2, FANCG, GADD45A, GADD45G, MGMT, RAD1,
RAD17, RAD18, RAD21, RAD51B, RAD9A, RBBP8, RDC1, REV1, RNF168, RNF8, SMC1A, SUMO1, TOP2A, TOPBP1, XRCC3, XRCC6BP1
Deregulation of cellular energetics [227,228]
Glycolysis ALDOA, ALDOB, ALDOC, BPGM, ENO1, ENO2, ENO3, GALM, GCK, GPI, HK2, HK3, PFKL, PGAM2, PGK1, PGK2, PGM1, PGM2, PGM3, PKLR,
TPI1
Gluconeogenesis FBP1, FBP2, G6PC, G6PC3, PC, PCK1, PCK2
Regulation PDK1, PDK2, PDK3, PDK4, PDP2, PDPR
TCA cycle ACLY, ACO1, ACO2, CS, DLAT, DLD, DLST, FH, IDH1, IDH2, IDH3A, IDH3B, IDH3G, MDH1, MDH1B, MDH2, OGDH, PC, PCK1, PCK2, PDHA1,
PDHB, SDHA, SDHB, SDHC, SDHD, SUCLA2, SUCLG1, SUCLG2
Pentose phosphate pathway G6PD, H6PD, PGLS, PRPS1, PRPS1L1, PRPS2, RBKS, RPE, RPIA, TALDO1, TKT
Glycogen metabolism GBE1, GYS1, GYS2, UGP2, AGL, PGM1, PGM2, PGM3, PYGL, PYGM, GSK3A, GSK3B, PHKA1, PHKB, PHKG1, PHKG2
Mitochondrial: Complex I NDUFA1, NDUFA10, NDUFA11, NDUFA2, NDUFA3, NDUFA4, NDUFA5, NDUFA6, NDUFA8, NDUFAB1, NDUFB10, NDUFB2, NDUFB3,
NDUFB4, NDUFB5, NDUFB6, NDUFB7, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS5, NDUFS6,
NDUFS7, NDUFS8, NDUFV1, NDUFV2, NDUFV3,
Mitochondrial: Complex II SDHA, SDHB, SDHC, SDHD
Mitochondrial: Complex III CYC1, UQCR11, UQCRC1, UQCRC2, UQCRFS1, UQCRH, UQCRQ
Mitochondrial: Complex IV COX4I1, COX5A, COX5B, COX6A1, COX6A2, COX6B1, COX6C, COX7A2, COX7A2L, COX7B, COX8A
Mitochondrial: Complex V ATP5A1, ATP5B, ATP5C1, ATP5F1, ATP5G1, ATP5G2, ATP5G3, ATP5H, ATP5I, ATP5J, ATP5J2, ATP5L, ATP5O, PPA1
Activator genes ARRDC3, ASB1, CYB561D1, DNAJB1, EDN1, GADD45B, HSPA1A, HSPA1B, LRP5L, MitoH1, MitoH2_12106, MitoH2_14573, MitoH2_4162,
MitoH2_5726, RNU11, SLC25A25
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ization platforms [244].
About 70% of the human genome transcribed to RNA will not serve
as a template for protein translation. Among them the long non-coding
RNAs (lncRNA), containing sequences of over 200 nucleotides in length,
are involved in the regulation of transcriptional and post-transcriptional
control of gene expression and epigenetic processes, such as chromatin
remodeling and histone modiﬁcation [245]. lncRNAs are deregulated in
several human cancers and are frequently expressed in disease in a
tissue-speciﬁc manner [246]. Serial analysis of gene expression (SAGE)
and its subsequent modiﬁcations (LongSAGE and SuperSAGE) use
short tags to count transcripts that later are mapped on assembled
genome sequences to allow quantitative analysis and identiﬁcation of
new transcripts [247–249]. Cap analysis gene expression (CAGE) is
based on the isolation and sequencing of short cDNA sequence tags
derived from the 5′ terminus of mRNAs, thus identifying the location
of transcriptional start points [250]. Functional lncRNAs have been
discovered using ChIP-seq by focusing on histone modiﬁcations that
are associated with active transcription [251]. RNA-seq provides the
most powerful tool in lncRNA discovery and expression analysis andallows the detection of low abundance transcripts with low background
noise [252]. RT-qPCR, northern blots and ﬂuorescence in situ hybridiza-
tions can verify the presence of single candidate lncRNAs in different
tissue and cell types identiﬁed from high-throughput data [253].
3. Outlook
Selecting the ideal analytic technique is based on the investigator's
goals, available equipment and also on ﬁnancial constraints. Multiplexing
strategies enable a more in-depth data collection from a single experi-
ment, yielding several values while controlling for variability, saving
time and relative cost and leading to more robust conclusions.
High throughput screening (HTS) allows rapid compoundanalysis in
low volume assay formats, such as in 384- or 1536-well plates and is
gaining increasing support with the development of automated optical
detection systems [254]. High content screening (HCS) is based on auto-
mated microscopy and image analysis and is able to measure multiple
cell physiology characteristics in real time. HCS allows screening of
enormously large libraries of molecules to discover new inhibitors of
cellular physiology, thereby enhancing the drug discovery process.
Table 7
List of widely applicable assays suitable for the analysis of multiple hallmark features.
Assay Hallmark Hallmark feature
Flow cytometry Sustaining proliferation Membrane integrity, DNA synthesis
Resisting cell death Morphological alternations
Genome fragmentation
Plasma membrane integrity
Mitochondrial membrane integrity and dysfunction
Intracellular Ca++ concentration
Caspase cascade detection
Immortality Telomere length
Genome instability DNA content changes
Metabolism Glucose uptake
Fluorescence microscopy Resisting cell death Genome fragmentation
Plasma membrane integrity
Mitochondrial membrane integrity and dysfunction
Intracellular Ca++ concentration
Caspase cascade detection
Migration/invasion Cell tracking, counting
Genome instability Karyotyping
Metabolism Glucose uptake
Multiwell reader (colorimetric,
spectrometric, ﬂuorimetric)
Sustaining proliferation Cell viability (metabolic assay)
Membrane integrity (LDH assay)
Amino acid binding
Resisting cell death Plasma membrane integrity
Mitochondrial membrane integrity and dysfunction
Immortality/senescence SA-β-gal reactivity at pH 6.0
Metabolism Glucose uptake/Glutathione uptake
Glucose trace
Rate limiting enzymes
OCR, ECAR
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proliferation [255–257], migration [258,259] and metastases [260,261].
Cytometers based on automated ﬂuorescence microscopy are sensitive
enough to detect single cells based on the strength of a ﬂuorescent sig-
nal [256]. Proliferation can be assessed by counting DAPI-labeled nuclei
and BrdU-incorporating cells separately, then evaluating the proportion
of cells in the S-phase based on the dual emission-images [258,262].
Viability and proliferation assays are relevant to evaluate additional
hallmarks that involve the analysis of similar physiological processes
within living cells. For example, the loss of membrane integrity is a sig-
nal of cell death, measured by dye exclusion or LDH release after a cyto-
toxic insult. Metabolic assays provide information not only about cell
viability but also about the extent of overall metabolic change. Dyes in-
corporated into DNA, such as PI or BrdU, also help to gain insight into
DNA content changes when evaluating genome instability.
Each and every hallmark possesses properties that can be analyzed
by immunoblot, RT-PCR, immunochemistry, immunoprecipitation,
RNA microarray or RNA-seq (see Table 6). In general, ﬂow cytometry,
ﬂuorescence microscopy, andmultiwell readers are also extremely ver-
satile tools thatwith proper sample preparation, allow the detection of a
vast number of hallmark features (summarized in Table 7).
In summary, here we have provided a link between available tech-
niques and the recognized hallmarks of cancer. Although our list is not
exhaustive, our aim is to include themost widely usedmethods.We en-
courage the reader to make an informed decision regarding assay selec-
tion to gain the maximum beneﬁt from existing tools.
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